Well, let’s start with the NP didn’t design th
Post# of 154140
(Total Views: 535)
Posted On: 03/08/2021 7:45:09 AM
Re: nmbr1stckpckr #81787
Well, let’s start with the NP didn’t design the trial comment.if you haven’t heard, CEOs are accountable for everything that happens in the company whether they had their hands in it or not. CEOs have been fired for activities in companies executed by people for to five layers below them who they don’t know.why ? Because CEOs recognize they are responsible for results.
Taking your emotions out of the picture , all Biotech execs understand that they have to hit certain targets to proceed thru trials, regardless of what they think of the FDA rules.they wouldn’t call a primary endpoint a primary endpoint if it didn’t mean anything.
Ultimately, if this stock was on the NASDAQ and the majority of shares were owned by large investment firms rather than the emotions of retail investors . At this point they would be looking at the big picture decisions such as was the decision to sidetrack into Covid , ultimately a decision that leads to delays in the core focus of the company at the time which was HIV and Cancer. If those studies and work to get them approved turn out to have been slowed to the point they fall behind the competition because we changed gears to go after Covid, which may never bare fruit it was a major failure in decision making by the CEO. And it’s up to the Chairman of the board to review that .
I don’t look at investing emotionally as apparently , you have full emotion in this stock. Investing is, or should be, pragmatic and reviewing facts. It could turn out we have a very good experimental drug but the management and navigation of this drug thru inexperienced hands , fails to get it to market. The BLA problem was a failure to acknowledge the skills required to do this work, thus delaying the approval from last Summer to perhaps this summer. The competition doesn’t wait and we can’t call a time out because of such mistakes
Taking your emotions out of the picture , all Biotech execs understand that they have to hit certain targets to proceed thru trials, regardless of what they think of the FDA rules.they wouldn’t call a primary endpoint a primary endpoint if it didn’t mean anything.
Ultimately, if this stock was on the NASDAQ and the majority of shares were owned by large investment firms rather than the emotions of retail investors . At this point they would be looking at the big picture decisions such as was the decision to sidetrack into Covid , ultimately a decision that leads to delays in the core focus of the company at the time which was HIV and Cancer. If those studies and work to get them approved turn out to have been slowed to the point they fall behind the competition because we changed gears to go after Covid, which may never bare fruit it was a major failure in decision making by the CEO. And it’s up to the Chairman of the board to review that .
I don’t look at investing emotionally as apparently , you have full emotion in this stock. Investing is, or should be, pragmatic and reviewing facts. It could turn out we have a very good experimental drug but the management and navigation of this drug thru inexperienced hands , fails to get it to market. The BLA problem was a failure to acknowledge the skills required to do this work, thus delaying the approval from last Summer to perhaps this summer. The competition doesn’t wait and we can’t call a time out because of such mistakes
(7)
(1)